Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Schering-Plough To Pay $165 Million To Shareholders For Clarinex Delay

This article was originally published in The Pink Sheet Daily

Executive Summary

The company is settling claims it failed to reveal that negative FDA inspection reports would delay approval of its allergy medicine.

You may also be interested in...



Schering Puts Last Nail In Clarinex' Coffin

Settlement of final patent cases means that generics will launch on Jan. 1, 2012.

Schering Puts Last Nail In Clarinex' Coffin

Settlement of final patent cases means that generics will launch on Jan. 1, 2012.

Merck/Schering: The Next Wave Of Consolidation

News of Pfizer's takeover of Wyeth has hardly had time to sink in and already a second mega-merger is shaking up big pharma. This time Merck is the buyer; the company announced March 9 that it proposes to acquire its cardiovascular joint venture partner Schering-Plough in a deal valued at $41.1 billion

Topics

UsernamePublicRestriction

Register

PS069133

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel